Covid-19: Mylan’s remdesivir will be available to patients in India in July at ₹4,8002 min read . Updated: 06 Jul 2020, 04:51 PM IST
- Mylan to launch generic remdesivir version in India at $64 per 100 mg vial, while Gilead has priced it at $2,340 per patient for wealthier nations
- Drug has been approved in India for treatment of suspected or lab-confirmed Covid-19 cases, Mylan NV says
New Delhi: Drugmaker Mylan NV said on Monday it secured approval to launch its generic version of Gilead Sciences Inc's Covid-19 treatment drug remdesivir in India this month at ₹4,800 per 100 mg vial, as infections surge in the world's third worst-hit country by the virus.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more